Clinical Trial Update: Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED) [Phase 1]

View source ↗

Summary

A Phase 1 Growth Factor Signature (GFS) Pilot Study MK0000-098 in Philadelphia chromosome-positive chronic myelogenous leukemia and Philadelphia chromosome-posi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Myelogenous Leukemia

Drugs mentioned

• Growth Factor Signature Pilot Study MK0000-098 (GFS MK0000-098)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia (CML), Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia (ALL) | Phase 1 | Status: TERMINATED | Results posted: 2011-10-10